

Innovation in Breast Cancer

iBC 2024

15th · 16th Feb
2024
VIRTUAL **FORMAT**



Sara M. Tolaney

Dana-Farber Cancer Institute, Boston, USA

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology. She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer. She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.

Physician

Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers

Associate Director, Susan F. Smith Center for Women's Cancers

Senior Physician

Associate Professor of Medicine, Harvard Medical School